share_log

Reneo Pharmaceuticals Receives Fast Track Designation From FDA For Mavodelpar In A Genotype Af Long-Chain Fatty Acid Oxidation Disorder

Reneo Pharmaceuticals Receives Fast Track Designation From FDA For Mavodelpar In A Genotype Af Long-Chain Fatty Acid Oxidation Disorder

Reneo Pharmicals因Mavodelpar在基因型Af長鏈脂肪酸氧化障礙中獲得美國食品藥品管理局的快速通道認證
Benzinga Real-time News ·  2023/01/31 07:42

Reneo Pharmaceuticals Receives Fast Track Designation From FDA For Mavodelpar In A Genotype Af Long-Chain Fatty Acid Oxidation Disorder

Reneo Pharmicals因Mavodelpar在基因型Af長鏈脂肪酸氧化障礙中獲得美國食品藥品管理局的快速通道認證

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論